Applying cytogenetic and molecular information in the clinic: Implications for the treatment of chronic myeloid leukemia

Alfonso Quintás-Cardama, Hagop Kantarjian, Jorge E. Cortés

Research output: Contribution to journalArticle

Abstract

The tyrosine kinase inhibitor (TKI) imatinib mesylate has changed dramatically the outcome of patients with chronic myeloid leukemia (CML). Most patients chieve a complete cytogenetic response (CCyR), and many also achieve profound molecular responses. These excellent clinical responses translate into very favorable long-term outcomes. The prognostic impact of achieving cytogenetic and molecular responses at specific time points on response duration and survival has made it even more important to appropriately monitor TKI response in patients with CML. To this end, sophisticated molecular techniques are increasingly available to clinical laboratories. The clinical implications of TKI response monitoring in CML are herein reviewed.

Original languageEnglish (US)
Pages (from-to)S14-S19
JournalClinical Lymphoma, Myeloma and Leukemia
Volume10
Issue numberSUPPL. 1
DOIs
StatePublished - Jun 2010

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cytogenetics
Protein-Tyrosine Kinases
Therapeutics
Survival

Keywords

  • BCR-ABL1
  • Dasatinib
  • Fluorescence in situ hybridization
  • Imatinib
  • Nilotinib

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Applying cytogenetic and molecular information in the clinic : Implications for the treatment of chronic myeloid leukemia. / Quintás-Cardama, Alfonso; Kantarjian, Hagop; Cortés, Jorge E.

In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 10, No. SUPPL. 1, 06.2010, p. S14-S19.

Research output: Contribution to journalArticle

@article{a66ba9859e5b4beb9694c7948fb79eb9,
title = "Applying cytogenetic and molecular information in the clinic: Implications for the treatment of chronic myeloid leukemia",
abstract = "The tyrosine kinase inhibitor (TKI) imatinib mesylate has changed dramatically the outcome of patients with chronic myeloid leukemia (CML). Most patients chieve a complete cytogenetic response (CCyR), and many also achieve profound molecular responses. These excellent clinical responses translate into very favorable long-term outcomes. The prognostic impact of achieving cytogenetic and molecular responses at specific time points on response duration and survival has made it even more important to appropriately monitor TKI response in patients with CML. To this end, sophisticated molecular techniques are increasingly available to clinical laboratories. The clinical implications of TKI response monitoring in CML are herein reviewed.",
keywords = "BCR-ABL1, Dasatinib, Fluorescence in situ hybridization, Imatinib, Nilotinib",
author = "Alfonso Quint{\'a}s-Cardama and Hagop Kantarjian and Cort{\'e}s, {Jorge E.}",
year = "2010",
month = "6",
doi = "10.3816/CLML.2010.s.002",
language = "English (US)",
volume = "10",
pages = "S14--S19",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2650",
publisher = "Cancer Media Group",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Applying cytogenetic and molecular information in the clinic

T2 - Implications for the treatment of chronic myeloid leukemia

AU - Quintás-Cardama, Alfonso

AU - Kantarjian, Hagop

AU - Cortés, Jorge E.

PY - 2010/6

Y1 - 2010/6

N2 - The tyrosine kinase inhibitor (TKI) imatinib mesylate has changed dramatically the outcome of patients with chronic myeloid leukemia (CML). Most patients chieve a complete cytogenetic response (CCyR), and many also achieve profound molecular responses. These excellent clinical responses translate into very favorable long-term outcomes. The prognostic impact of achieving cytogenetic and molecular responses at specific time points on response duration and survival has made it even more important to appropriately monitor TKI response in patients with CML. To this end, sophisticated molecular techniques are increasingly available to clinical laboratories. The clinical implications of TKI response monitoring in CML are herein reviewed.

AB - The tyrosine kinase inhibitor (TKI) imatinib mesylate has changed dramatically the outcome of patients with chronic myeloid leukemia (CML). Most patients chieve a complete cytogenetic response (CCyR), and many also achieve profound molecular responses. These excellent clinical responses translate into very favorable long-term outcomes. The prognostic impact of achieving cytogenetic and molecular responses at specific time points on response duration and survival has made it even more important to appropriately monitor TKI response in patients with CML. To this end, sophisticated molecular techniques are increasingly available to clinical laboratories. The clinical implications of TKI response monitoring in CML are herein reviewed.

KW - BCR-ABL1

KW - Dasatinib

KW - Fluorescence in situ hybridization

KW - Imatinib

KW - Nilotinib

UR - http://www.scopus.com/inward/record.url?scp=77957357294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957357294&partnerID=8YFLogxK

U2 - 10.3816/CLML.2010.s.002

DO - 10.3816/CLML.2010.s.002

M3 - Article

C2 - 20529803

AN - SCOPUS:77957357294

VL - 10

SP - S14-S19

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2650

IS - SUPPL. 1

ER -